FDA grants accelerated approval to AstraZeneca’s Calquence for mantle cell lymphoma treatment

AstraZeneca has achieved a significant milestone with the early FDA approval of Calquence (acalabrutinib) for the treatment of adult patients with mantle cell lymphoma who ... Read More